Table 1.
Mycophenolic acid (MPA) dose-normalized (dn) AUC0-12h according to SLCO, UGT or ABCC2 Single Nucleotide Polymorphisms (SNPs) in patients co-treated with cyclosporine
| Gene | SNP | Patients genotypes (n) | MPA dn-AUC0-12h (mg.h/l)/g | P values |
|---|---|---|---|---|
| SLCO1B3 | T334G | TT (n=6) | 42.7±18.4 | 0.4747 |
| TG (n=32) | 48.6±22.9 | |||
| GG (n=76) | 42.7±20.2 | |||
| G767C | GG (n= 79) | 47.1±23.2 | 0.0469 | |
| GC (n= 36) | 38.1±12.4 | |||
| SLCO1B1 | T521C | TT (n=75) | 44.8±20.7 | 0.7507 |
| TC (n=36) | 43.7±22.1 | |||
| CC (n=4) | 38.6±10.9 | |||
| A388G | AA (n=37) | 45.5±17.1 | 0.2800 | |
| AG (n=52) | 44.1±22.2 | |||
| GG (n=26) | 42.8±23.3 | |||
| C463A | CC (n=83) | 43.6±18.3 | 0.9717 | |
| CA (n=30) | 46.3±27.0 | |||
| AA (n=2) | 42.8±25.0 | |||
| UGT1A8 | C518G | CC (n=59) | 43.7±18.9 | 0.9066 |
| CG (n=50) | 44.1±22.1 | |||
| GG (n=6) | 51.4±29.3 | |||
| UGT1A9 | C-440T | CC (n=69) | 40.8±15.3 | 0.2721 |
| CT (n=39) | 49.2±27.1 | |||
| TT (n=7) | 50.7±24.0 | |||
| T-275A and/or C-2152T* | TTandCC(n=101) | 44.1±21.2 | 0.4498 | |
| TAandCT or CC(n=12) | 47.8±19.1 | |||
| AA and TT (n=2) | 31.8±7.9 | |||
| T98C | TT (n=105) | 43.7±21.1 | 0.0634 | |
| TC (n=10) | 50.7±17.1 | |||
| ABCC2 | C-24T | CC (n=68) | 40.2±14.5 | 0.0087 |
| CT (n=35) | 53.6±26.0 | |||
| TT (n=12) | 39.9±26.7 | |||
*
SNPs in strong linkage disequilibrium: D′=1; r2=0.87